Grifols delivered a strong financial performance in the first half of 2025 with significant revenue and EBITDA growth, successful pipeline execution, and a reinstated dividend, despite challenges in foreign exchange volatility and pricing pressures in the Chinese market.
Company Guidance
During Grifols' fiscal year 2025 Q2 call, the company reported a strong set of results, with key financial metrics showcasing significant growth. Revenue for the first half of 2025 reached EUR 3.7 billion, marking a 7% increase on a reported basis and 10.1% like-for-like at constant currency. Adjusted EBITDA rose to EUR 876 million, reflecting a 12.7% increase on a reported basis and 20.1% like-for-like. The company achieved a leverage ratio of 4.2x, and free cash flow improved by nearly EUR 200 million year-over-year. Grifols also announced the reinstatement of dividend payments, with an interim dividend of EUR 0.15 per share. The biopharma segment drove growth, particularly through the immunoglobulin franchise, which grew by 17.8% like-for-like. Despite challenges like foreign exchange volatility and pricing pressure in the albumin market, Grifols remains confident in achieving its full-year guidance, backed by strategic efforts in cost reduction, operational efficiencies, and innovation, such as the upcoming launch of fibrinogen in Europe and the U.S.
Strong Revenue Growth
Grifols achieved revenue of EUR 3.7 billion in the first half of 2025, representing a year-over-year increase of 7% on a reported basis and 10.1% like-for-like at constant currency.
Adjusted EBITDA Increase
Adjusted EBITDA reached EUR 876 million, a 12.7% increase on a reported basis and 20.1% like-for-like at constant currency.
Dividend Reinstatement
Grifols announced a EUR 0.15 per share interim dividend, reinstating dividend payments after over 4 years, reflecting strong financial performance and confidence in future prospects.
Biopharma Segment Growth
Biopharma segment reported 8.2% growth, driven by a 12.5% increase in the IG franchise at constant currency, showcasing strong market demand.
Pipeline Advancements
Significant progress in the innovation pipeline, including the upcoming launch of fibrinogen in Europe (Q4 2025) and the US (first half of 2026).
Grifols SA (GRFS) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GRFS Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 29, 2025
$9.96
$10.36
+4.02%
May 12, 2025
$7.00
$7.63
+9.00%
Feb 26, 2025
$7.28
$7.83
+7.55%
Nov 07, 2024
$8.93
$9.37
+4.93%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Grifols SA (GRFS) report earnings?
Grifols SA (GRFS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).
What is Grifols SA (GRFS) earnings time?
Grifols SA (GRFS) earnings time is at Nov 06, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.